Top Page
EVE Health Group Limited
(Sydney:EVE)
EVE Health Group Limited (EVE) vs. iShares MSCI Australia ETF (EWA)
EVE Health Group Limited Business Overview & Revenue Model
EVE Health Group Limited Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.13M | 2.33M | 2.01M | 2.80M | 2.31M |
| Gross Profit | 876.96K | -337.00K | -1.00M | 1.31M | 873.73K |
| EBITDA | -1.51M | -2.16M | -4.53M | -3.26M | -2.72M |
| Net Income | -1.90M | -4.04M | -5.37M | -3.63M | -2.40M |
Balance Sheet | |||||
| Total Assets | 2.52M | 4.13M | 8.07M | 11.92M | 14.11M |
| Cash, Cash Equivalents and Short-Term Investments | 106.17K | 192.48K | 1.10M | 3.16M | 5.14M |
| Total Debt | 74.85K | 4.28K | 492.39K | 1.01M | 584.31K |
| Total Liabilities | 1.30M | 1.01M | 1.14M | 1.74M | 1.12M |
| Stockholders Equity | 1.22M | 3.12M | 6.93M | 10.19M | 12.99M |
Cash Flow | |||||
| Free Cash Flow | -1.11M | -1.65M | -3.80M | -2.51M | -3.48M |
| Operating Cash Flow | -1.11M | -1.65M | -3.77M | -2.24M | -3.16M |
| Investing Cash Flow | 874.27K | 498.46K | -26.05K | -263.38K | -557.11K |
| Financing Cash Flow | 146.37K | 240.69K | 1.74M | 529.43K | 8.51M |
EVE Health Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$33.50M | ― | ― | -5.86% | 98.26% | ||
51 Neutral | $7.73B | -0.08 | -44.77% | 2.23% | 22.72% | -1.44% | |
43 Neutral | €5.16M | ― | ― | ― | 98.35% | ||
42 Neutral | AU$5.10M | ― | -76.28% | ― | 5.01% | 74.84% | |
36 Underperform | AU$9.03M | ― | -548.03% | ― | 192.34% | 68.06% | |
34 Underperform | AU$7.88M | ― | -105.17% | ― | -3.82% | 51.47% | |
31 Underperform | AU$3.70M | ― | ― | -16.29% | 58.77% |
EVE Health Group Limited Corporate Events
EVE Health Group Limited has completed the acquisition of Nextract Pty Ltd, enhancing its capabilities in solubility delivery and formulation expertise. This acquisition supports the company’s entry into high-growth markets with products like Libbo for erectile dysfunction and Dyspro for dysmenorrhea. The company has secured a national prescribing agreement with TeleDocs to promote these products across Australia. Additionally, EVE has achieved regulatory milestones, confirming the stability and shelf life of its products, and is actively exploring distribution options for Dyspro. Leadership changes have been announced, with new appointments aimed at strengthening the company’s R&D and commercial strategies.
EVE Health Group has confirmed that it has met the regulatory requirements to launch its lead products, Libbo and Dyspro, in Australia under the TGA medicines access pathways. This achievement allows the company to proceed with its commercial launch ahead of schedule, with the first prescriptions expected by the end of 2025. The products, targeting significant unmet needs in men’s and women’s health, are developed in fast-acting oral dissolvable formats. EVE is also planning for international expansion following the initial Australian market entry.
EVE Health Group Limited has submitted its first commercial purchase order for Dyspro™, a proprietary cannabinoid-based product designed to alleviate dysmenorrhoea, marking a significant milestone in its operational expansion into prescription pharmaceuticals. The product is set to be manufactured in Australia and distributed through a network of authorized prescribers, with the company actively seeking distribution partners to ensure timely and compliant delivery. This development positions EVE to capitalize on the growing global market for dysmenorrhoea treatments, projected to reach USD 20 billion by 2035, and addresses a significant unmet need in women’s health.
EVE Health Group Limited has announced the quotation of 902,766 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 26, 2025. This move is part of a transaction previously announced and could potentially impact the company’s market presence by increasing its liquidity and accessibility for investors.
EVE Health Group has successfully completed its Share Purchase Plan (SPP), allowing eligible shareholders to purchase new fully paid ordinary shares at $0.036 per share, the same price as a recent placement. The company received applications totaling $32,500, resulting in the issuance of 902,766 new shares, which will rank equally with existing shares, potentially strengthening its financial position and shareholder base.
EVE Health Group Limited has entered into a national prescribing agreement with TeleDocs Clinic for its oral soluble film for erectile dysfunction and gummy formulation for dysmenorrhea. This strategic partnership will enable EVE to leverage TeleDocs’ extensive network of over 3,500 pharmacies across Australia, enhancing product launch plans and patient access ahead of regulatory approvals. The collaboration will also involve practitioner education, digital integration, and promotional support, positioning EVE for a successful national rollout of its products.
EVE Health Group has announced a live investor webinar to update shareholders and investors on its strategy following the acquisition of Nextract Pty Ltd. The webinar will feature Mr. Damian Wood, the incoming CEO, who will discuss the company’s development pipeline and focus areas post-acquisition, as well as upcoming commercial and regulatory milestones. This event signifies EVE’s proactive approach to engaging with its stakeholders and highlights its strategic direction in the health industry.
EVE Health Group Limited has announced that Alasdair Cooke and several associated entities have ceased to be substantial holders in the company as of June 12, 2025. This change, primarily due to dilution, affects a significant number of fully paid ordinary shares and may impact the company’s ownership structure and voting dynamics.
EVE Health Group Limited has announced that Stuart Gunzburg has become a substantial holder in the company as of June 12, 2025, with a 19.38% voting power through various entities. This development could potentially influence the company’s strategic decisions and shareholder dynamics, given the significant voting power now held by Gunzburg.
EVE Health Group Limited has announced the appointment of Stuart Gunzburg as a director, effective June 12, 2025. Gunzburg holds significant interests in the company, including 7,936,508 ordinary shares directly and additional shares through entities where he serves as director or shareholder. This appointment and Gunzburg’s substantial shareholding may influence the company’s strategic direction and stakeholder confidence.
EVE Health Group Limited has completed the acquisition of Nextract Pty Ltd, a biotech company specializing in solubility-enhancing drug delivery systems. This strategic move positions EVE to expand its presence in the regulated healthcare sector, particularly targeting the erectile dysfunction and dysmenorrhea markets with innovative dosage formats. The acquisition was settled through the issuance of shares, and a $1 million placement was completed to fund Nextract’s integration and initial manufacturing scale-up. The company also announced significant board and management changes, including the appointment of Dr. Stuart Gunzburg as Chief Scientific Officer and Executive Director, and the transition of Mr. Bill Fry to a Non-Executive Director role. This acquisition and leadership restructuring are expected to accelerate EVE’s growth and enhance its market positioning.
EVE Health Group Limited has announced the quotation of 113,444,444 ordinary fully paid securities on the ASX, effective June 12, 2025. This move is part of a previously announced transaction, potentially impacting the company’s market presence and offering stakeholders an opportunity to engage with the company’s growth strategy.
EVE Health Group Limited has issued a prospectus for several offers, including Placement Shares, Nextract Vendors Shares, Lead Manager Shares, and SPP Shares, all priced at 3.6 cents per share. This transaction-specific prospectus, prepared under section 713 of the Corporations Act, is aimed at raising capital through the ASX for the company’s ongoing operations, with implications for investors to consider the suitability of these securities in light of their own financial circumstances.
EVE Health Group Limited announced a significant change in the director’s interest in securities due to a consolidation of shares. The consolidation, approved at the company’s General Meeting, reduced the number of shares held by Director Gregory William Fry and his related entities, impacting the overall share distribution and potentially affecting the company’s market positioning and shareholder value.
EVE Health Group has completed a share consolidation on a forty-to-one basis, as approved by shareholders. This move results in a new capital structure with 131,862,715 ordinary shares. The consolidation aims to streamline the company’s capital structure, potentially enhancing its market position and operational efficiency. Trading on a normal T+2 settlement basis will resume on 12 June 2025.
EVE Health Group has commenced stability testing for its new oral products aimed at treating erectile dysfunction and dysmenorrhea, marking a significant step towards regulatory approval in Australia. These products, developed by Nextract, use proven active pharmaceutical ingredients in novel dissolvable formats for improved patient experience. The testing is a critical part of the regulatory submission process, with approvals anticipated by the end of 2025. This development aligns with EVE’s strategy to target high-value, under-served markets with unmet clinical needs, leveraging Australia’s regulatory pathways to accelerate access to prescription medicines. Additionally, EVE has completed its registration with the Therapeutic Goods Administration as a sponsor and manufacturer, further advancing its health and wellness strategy.
EVE Health Group announced that all resolutions at their General Meeting were passed, including the acquisition of Nextract Pty Ltd. This acquisition will lead to leadership changes, with Mr. Stuart Gunzburg joining the Board and Mr. Damian Wood becoming the CEO. The integration of Nextract is expected to enhance EVE’s expansion into regulated pharmaceutical markets, potentially strengthening its industry position and offering new opportunities for stakeholders.
Eve Health Group Limited is focusing on reformulating a drug targeting the erectile dysfunction market, which is valued at $5.3 billion. The new formulation aims to enhance solubility for faster action and higher efficacy, potentially impacting the company’s operations and market positioning by tapping into a significant market segment.
EVE Health Group Limited has requested a trading halt on its securities pending the announcement of the results from a general meeting. This meeting will consider a transaction under ASX Listing Rule 11.1, and the trading halt will remain until the results are disclosed, impacting the company’s market activities and potentially its strategic direction.